8-Chloro-4-[1-dimethylamino-meth-(E)-ylidene]-1-phenyl-3,4-dihydro-benzo[c]azepin-5-one | 58582-16-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 8-Chloro-4-[1-dimethylamino-meth-(E)-ylidene]-1-phenyl-3,4-dihydro-benzo[c]azepin-5-one
• 英文别名: 8-Chloro-4-dimethylaminomethylidene-1-phenyl-3,4-dihydro-2-benzazepin-5-one；8-chloro-4-(dimethylaminomethylidene)-1-phenyl-3H-2-benzazepin-5-one
• CAS: 58582-16-4
• 化学式: C₁₉H₁₇ClN₂O
• 分子量: 324.81
• InChiKey: GBTZWDORYJOWFT-UHFFFAOYSA-N

物化性质

• 沸点：
  470.1±45.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-Chloro-4-[1-dimethylamino-meth-(E)-ylidene]-1-phenyl-3,4-dihydro-benzo[c]azepin-5-one 在 乙酸铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 9-Chloro-2-oxo-7-phenyl-2,5-dihydro-1H-1,6-diaza-dibenzo[a,c]cycloheptene-3-carboxylic acid
  参考文献：
  名称：

  Walser, Armin; Todaro, Louis, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 1299 - 1304

  摘要：

  DOI：
• 作为产物：
  描述：

  8-chloro-1-phenyl-3,4-dihydro-5H-2-benzazepin-5-one 、 N,N-二甲基甲酰胺二甲基缩醛 在 乙醚 作用下， 反应 1.0h， 以to yield the 8-chloro-4-dimethylaminomethylidene-1-phenyl-3,4-dihydro-2-benzazepin-5-one的产率得到8-Chloro-4-[1-dimethylamino-meth-(E)-ylidene]-1-phenyl-3,4-dihydro-benzo[c]azepin-5-one
  参考文献：
  名称：

  Pyrazolobenzazepines

  摘要：

  6-芳基-1-或2H，4H-吡唑并[4,3-d]（2）-苯并吲哚啉，例如公式##STR1## R = H或烷基，R.degree. = H，烷基，（HO，烷氧基，氨基）-烷基，芳基甲基，芳基或酰基，R' = h，oh或烷基，R" = h，烷基，烷氧基，卤素或CF.sub.3 N-其氧化物或这些化合物的治疗上有用的酸盐具有抗焦虑和抗抑郁作用。

  公开号：

  US04022801A1

文献信息

• Pyrimido-2-benzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04481142A1

  公开（公告）日：1984-11-06

  There is presented compounds of the formula ##STR1## wherein A is selected from the group consisting of ##STR2## R.sub.1 is selected from the group consisting of hydrogen, chlorine, bromine, lower alkyl, the group NR.sub.4 R.sub.5, the group --CH.sub.2 --CO--R.sub.7, the group--NH(CH.sub.2).sub.m NR.sub.8 R.sub.9, hydroxy, lower alkoxy, mercapto and lower alkyl mercapto; R.sub.2 is selected from the group consisting of hydrogen, amino and dilower alkyl amino; R.sub.3 is selected from the group consisting of hydrogen, lower acyloxy and hydroxy; X is selected from the group consisting of hydrogen, halogen, trifluoromethyl, ethyl, .alpha.-hydroxy ethyl and acetyl; Y is hydrogen or halogen; R.sub.4 and R.sub.5 are hydrogen or lower alkyl or together with their co-bonded nitrogen atom form a five to seven membered heterocyclic group; R.sub.7 is selected from the group consisting of hydroxy lower alkoxy and NR.sub.8 R.sub.9 ; R.sub.8 and R.sub.9 are hydrogen or lower alkyl; n is 0 or 1 and m is 1 to 7 with the limitations that (1) at least one of R.sub.1 and R.sub.2 are hydrogen, (2) when R.sub.3 is lower acyloxy or hydroxy, A is the group (a), X is hydrogen, halogen, trifluoromethyl, ethyl or acetyl and R.sub.1 is the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9, then R.sub.8 and R.sub.9 are lower alkyl, (3) when A is group (d) and R.sub.1 is the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9 then R.sub.8 and R.sub.9 are lower alkyl and (4) when n is 1, R.sub.1 is hydrogen, lower alkyl, lower alkoxy, chlorine, bromine or the group --CH.sub.2 --CO-- R.sub.7 with R.sub.7 as above then A is the group (a) or (b) and the pharmaceutically acceptable salts thereof. The compounds exhibit pharmacological activity as anxiolytics and sedatives. Also presented Are various novel intermediates and processes to produce the above end products.

  该文中介绍了一些化合物，其化学式为##STR1## 其中A从以下组中选择：##STR2## R1从以下组中选择：氢、氯、溴、低碳基、基团NR4R5、基团--CH2--CO--R7、基团--NH(CH2)mNR8R9、羟基、低烷氧基、巯基和低烷基巯基；R2从以下组中选择：氢、氨基和二低烷基氨基；R3从以下组中选择：氢、低酰氧基和羟基；X从以下组中选择：氢、卤素、三氟甲基、乙基、α-羟基乙基和乙酰基；Y为氢或卤素；R4和R5为氢或低烷基，或与它们共键合的氮原子形成五元至七元杂环基团；R7从以下组中选择：羟基低烷氧基和NR8R9；R8和R9为氢或低烷基；n为0或1，m为1至7，限制为：(1)R1和R2中至少有一个为氢；(2)当R3为低酰氧基或羟基时，A为(a)组，X为氢、卤素、三氟甲基、乙基或乙酰基，R1为基团--NH(CH2)mNR8R9，则R8和R9为低烷基；(3)当A为(d)组，R1为基团--NH(CH2)mNR8R9时，则R8和R9为低烷基；(4)当n为1，R1为氢、低烷基、低烷氧基、氯、溴或基团--CH2--CO--R7，其中R7如上所述，则A为(a)或(b)组及其药学上可接受的盐。这些化合物表现出抗焦虑和镇静的药理活性。此外，还介绍了各种新型中间体和生产上述终产品的工艺。
• Pyrimido-2-benzazepines and intermediates in their preparation
  申请人：Hoffmann-La Roche Inc.

  公开号：US04547581A1

  公开（公告）日：1985-10-15

  There is presented compounds of the formula ##STR1## wherein A is selected from the group consisting of ##STR2## R.sub.1 is selected from the group consisting of hydrogen, chlorine, bromine, lower alkyl, the group NR.sub.4 R.sub.5, the group --CH.sub.2 --CO--R.sub.7, the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9, hydroxy, lower alkoxy, mercapto and lower alkyl mercapto; R.sub.2 is selected from the group consisting of hydrogen, amino and di-lower alkyl amino; R.sub.3 is selected from the group consisting of hydrogen, lower acyloxy and hydroxy; X is selected from the group consisting of hydrogen, halogen, trifluoromethyl, ethyl, .alpha.-hydroxy ethyl and acetyl; Y is hydrogen or halogen; R.sub.4 and R.sub.5 are hydrogen or lower alkyl or together with their co-bonded nitrogen atom form a five to seven membered heterocyclic group; R.sub.7 is selected from the group consisting of hydroxy lower alkoxy and NR.sub.8 R.sub.9 ; R.sub.8 and R.sub.9 are hydrogen or lower alkyl; n is 0 or 1 and m is 1 to 7 with the limitations that (1) at least one of R.sub.1 and R.sub.2 are hydrogen, (2) when R.sub.3 is lower acyloxy or hydroxy, A is the group (a), X is hydrogen, halogen, trifluoromethyl, ethyl or acetyl and R.sub.1 is the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9, then R.sub.8 and R.sub.9 are lower alkyl, (3) when A is group (d) and R.sub.1 is the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9 then R.sub.8 and R.sub.9 are lower alkyl and (4) when n is 1, R.sub.1 is hydrogen, lower alkyl, lower alkoxy, chlorine, bromine or the group --CH.sub.2 --CO--R.sub.7 with R.sub.7 as above then A is the group (a) or (b) and the pharmaceutically acceptable salts thereof. The compounds exhibit pharmacological activity as anxiolytics and sedatives. Also presented are various novel intermediates and processes to produce the above end products.

  该文献介绍了公式为##STR1##的化合物，其中A选自以下组中的一种：##STR2## R.sub.1选自以下组中的一种：氢、氯、溴、低烷基、基团NR.sub.4 R.sub.5、基团--CH.sub.2 --CO--R.sub.7、基团--NH(CH.sub.2).sub.m NR.sub.8 R.sub.9、羟基、低烷氧基、巯基和低烷基巯基；R.sub.2选自以下组中的一种：氢、氨基和二低烷基氨基；R.sub.3选自以下组中的一种：氢、低酰氧基和羟基；X选自以下组中的一种：氢、卤素、三氟甲基、乙基、α-羟乙基和乙酰基；Y为氢或卤素；R.sub.4和R.sub.5为氢或低烷基，或与它们的共键氮原子形成五元至七元杂环基团；R.sub.7选自以下组中的一种：羟基低烷氧基和NR.sub.8 R.sub.9；R.sub.8和R.sub.9为氢或低烷基；n为0或1，m为1至7，限制条件为（1）R.sub.1和R.sub.2中至少有一个为氢，（2）当R.sub.3为低酰氧基或羟基时，A为组（a），X为氢、卤素、三氟甲基、乙基或乙酰基，R.sub.1为基团--NH(CH.sub.2).sub.m NR.sub.8 R.sub.9，则R.sub.8和R.sub.9为低烷基，（3）当A为组（d）且R.sub.1为基团--NH(CH.sub.2).sub.m NR.sub.8 R.sub.9时，则R.sub.8和R.sub.9为低烷基，（4）当n为1，R.sub.1为氢、低烷基、低烷氧基、氯、溴或基团--CH.sub.2 --CO--R.sub.7（其中R.sub.7如上所述）时，A为组（a）或（b），以及其药学上可接受的盐。这些化合物表现出抗焦虑和镇静的药理活性。此外，还提供了各种新颖的中间体和生产上述终产品的过程。
• Pyrazolobenzazepines
  申请人：Ciba-Geigy Corporation

  公开号：US03947585A1

  公开（公告）日：1976-03-30

  6-Aryl-1 or 2H,4H-pyrazolo[4,3-d](2)-benzazepines, e.g. those of the formula ##SPC1## R = h or alkyl R.sup.o = H, alkyl, (HO, alkoxy, amino)-alkyl, aralkyl or aryl R' = h, oh or alkyl R" = h, alkyl, alkoxy, halo or CF.sub.3 5,6-dihydro- or 5-alkyl-5,6-dihydro-derivatives, N-oxides, acyl derivatives or therapeutically useful acid addition salts thereof exhibit antianxiety and antidepressant effects.

  6-芳基-1或2H,4H-吡唑并[4,3-d](2)-苯并氮杂环化合物，例如公式##SPC1##中的化合物： R = H或烷基 R.sup.o = H，烷基，(HO，烷氧基，氨基)-烷基，芳基烷基或芳基 R' = H，OH或烷基 R" = H，烷基，烷氧基，卤素或CF.sub.3 5,6-二氢或5-烷基-5,6-二氢衍生物，N-氧化物，酰基衍生物或具有治疗用途的酸加成盐具有抗焦虑和抗抑郁作用。
• Walser, Armin; Todaro, Louis, Journal of Heterocyclic Chemistry, <hi>1989</hi>, vol. 26, p. 1299 - 1304
  作者：Walser, Armin、Todaro, Louis

  DOI：——

  日期：——